[go: up one dir, main page]

AR002728A1 - Un procedimiento para inhibir la fotodescomposicion de 2-oxindol-1- carboxamidas 3-sustituidas y una composicion farmaceutica que comprende dichaoxindol-carboxamida asi inhibida. - Google Patents

Un procedimiento para inhibir la fotodescomposicion de 2-oxindol-1- carboxamidas 3-sustituidas y una composicion farmaceutica que comprende dichaoxindol-carboxamida asi inhibida.

Info

Publication number
AR002728A1
AR002728A1 ARP960101956A AR10195696A AR002728A1 AR 002728 A1 AR002728 A1 AR 002728A1 AR P960101956 A ARP960101956 A AR P960101956A AR 10195696 A AR10195696 A AR 10195696A AR 002728 A1 AR002728 A1 AR 002728A1
Authority
AR
Argentina
Prior art keywords
carboxamide
substituted
carboxamides
inhibited
inhibiting
Prior art date
Application number
ARP960101956A
Other languages
English (en)
Inventor
Willard C Newlin Jr
Sharon M Laughlin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR002728A1 publication Critical patent/AR002728A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883Capsule finishing, e.g. dyeing, aromatising, polishing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polymerisation Methods In General (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

La presente invención se refiere a un procedimiento para inhibir la fotodescomposición de 2-oxindol-1-carboxamidas 3-sustituidas de fórmula (I), yla forma enólica del mismo o una sal de base farmacéuticamente aceptable del mismo en la queX es H, Cl o F; Y es H o Cl; y R es bencilo o tienilo, cada unoopcionalmente sustituido con Cl o F; donde dicha carboxamida es un medicamento y dicha fotodescomposición es causada por una luz que procede de una fuenteluminosa, caracterizado porque un material fotoabsorbente es puesto en contacto íntimo con dicha carboxamida por medio del mezclado con ella,revistiéndola, o incorporándola para esto en forma de dosificación, por lo cual dicha luz de dicha fuente de luz es substancialmenteimpedida de incidir o deotra manera de degradar o descomponer dicha carboxamida. Particularmente dicha forma de dosificación es un comprimido o una cápsula. Además, la invención serefiere a una composición farmacéutica que comprende dicha oxindol-carboxamida así inhibida.
ARP960101956A 1995-04-24 1996-03-28 Un procedimiento para inhibir la fotodescomposicion de 2-oxindol-1- carboxamidas 3-sustituidas y una composicion farmaceutica que comprende dichaoxindol-carboxamida asi inhibida. AR002728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000287 WO1996033701A1 (en) 1995-04-24 1995-04-24 Inhibiting photodecomposition of 3-substituted-2-oxindoles

Publications (1)

Publication Number Publication Date
AR002728A1 true AR002728A1 (es) 1998-04-29

Family

ID=36997502

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101956A AR002728A1 (es) 1995-04-24 1996-03-28 Un procedimiento para inhibir la fotodescomposicion de 2-oxindol-1- carboxamidas 3-sustituidas y una composicion farmaceutica que comprende dichaoxindol-carboxamida asi inhibida.

Country Status (30)

Country Link
EP (1) EP0827399A1 (es)
JP (1) JPH10506635A (es)
KR (1) KR100189585B1 (es)
CN (1) CN1053667C (es)
AP (1) AP607A (es)
AR (1) AR002728A1 (es)
AU (1) AU692378B2 (es)
BG (1) BG100531A (es)
BR (1) BR9602024A (es)
CO (1) CO4700418A1 (es)
FI (1) FI973988A0 (es)
HR (1) HRP960194A2 (es)
HU (1) HU216544B (es)
IL (1) IL117969A0 (es)
IS (1) IS4339A (es)
MA (1) MA23848A1 (es)
NO (1) NO961622L (es)
NZ (1) NZ286432A (es)
OA (1) OA10286A (es)
PE (1) PE34397A1 (es)
RO (1) RO113305B1 (es)
RU (1) RU2109510C1 (es)
SG (1) SG64924A1 (es)
SI (1) SI9600133A (es)
SK (1) SK51296A3 (es)
TR (1) TR199600300A2 (es)
UA (1) UA42739C2 (es)
WO (1) WO1996033701A1 (es)
YU (1) YU25096A (es)
ZA (1) ZA963210B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246323B2 (en) 2017-12-29 2022-02-15 Kraft Foods Group Brands Llc Oxidative stability of oil-in-water emulsions using natural stabilizers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136282A1 (de) * 1981-09-12 1983-03-24 Hoechst Ag "verfahren zur stabilisierung photoinstabiler arzneistoffe sowie stabilisierte arzneizubereitungen"
HUT59592A (en) * 1990-07-20 1992-06-29 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of solid medical products
TW438798B (en) * 1992-10-07 2001-06-07 Pfizer 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions

Also Published As

Publication number Publication date
NO961622L (no) 1996-10-25
NZ286432A (en) 1998-05-27
TR199600300A2 (tr) 1996-11-21
EP0827399A1 (en) 1998-03-11
OA10286A (en) 1997-09-19
KR960037656A (ko) 1996-11-19
CN1139110A (zh) 1997-01-01
HUP9601057A3 (en) 1997-05-28
HUP9601057A2 (en) 1997-04-28
ZA963210B (en) 1997-10-23
FI973988L (fi) 1997-10-17
FI973988A7 (fi) 1997-10-17
FI973988A0 (fi) 1997-10-17
JPH10506635A (ja) 1998-06-30
AP607A (en) 1997-08-27
AP9600787A0 (en) 1996-04-30
PE34397A1 (es) 1997-09-29
NO961622D0 (no) 1996-04-23
IL117969A0 (en) 1996-08-04
IS4339A (is) 1996-10-25
KR100189585B1 (ko) 1999-06-01
MA23848A1 (fr) 1996-12-31
HRP960194A2 (en) 1998-02-28
RU2109510C1 (ru) 1998-04-27
AU692378B2 (en) 1998-06-04
BG100531A (bg) 1997-06-30
RO113305B1 (ro) 1998-06-30
CO4700418A1 (es) 1998-12-29
BR9602024A (pt) 1998-10-06
WO1996033701A1 (en) 1996-10-31
HU216544B (hu) 1999-07-28
HU9601057D0 (en) 1996-06-28
AU5085196A (en) 1996-11-07
SI9600133A (en) 1996-10-31
UA42739C2 (uk) 2001-11-15
YU25096A (sh) 1998-08-14
CN1053667C (zh) 2000-06-21
SK51296A3 (en) 1997-04-09
SG64924A1 (en) 1999-05-25

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
TW200509905A (en) Pharmaceutical compositions of atorvastatin
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
EA200000245A1 (ru) Быстро дезинтегрирующие таблетки метилцеллюлозы
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
BR0213355A (pt) composições farmacêuticas
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
LT2001119A (en) Pharmaceutical formulations comprising intranasal morphine and use thereof
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
ATE273693T1 (de) Proteinhaltige arzneimittel
TW200503689A (en) Pharmaceutical compositions of atorvastatin
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
HUP9901260A3 (en) Optically active phenylpyrimidine derivative as analgesic agent, process for producing it, pharmaceutical composition containing it and its intermediate
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
AR002728A1 (es) Un procedimiento para inhibir la fotodescomposicion de 2-oxindol-1- carboxamidas 3-sustituidas y una composicion farmaceutica que comprende dichaoxindol-carboxamida asi inhibida.
MA27662A1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede